临床试验中关于肉症的结果:系统性审查和元分析
Michaela Rippl1, Katharina Müller1, Sebastian Martini1
1Department of Medicine IV/Geriatrics, LMU University Hospital, LMU Munich, Ziemssenstr. 5, 80336 Munich, Germany.
The journal of nutrition, health & aging
|March 4, 2026
概括
这次系统性审查发现,在肉症干预研究中存在很高的异质性,这阻碍了比较. 标准化终点,如ESCEO的终点,对于评估老年人治疗效果至关重要.
科学领域:
- 老年医学 老年医学
- 临床试验 临床试验
- 肌肉骨健康 肌肉骨健康
背景情况:
- 共同的终点对于改善干预研究质量和可比性至关重要.
- 该ESCEO确定了适合的终点,用于萨尔科佩尼亚治疗试验.
- 这项研究分析了用于麻症干预的随机对照试验的终点.
研究的目的:
- 审查在肉症干预试验中使用的终点.
- 评估与ESCEO推的终点的对应性.
- 确定是否定义了临床重要差异最小值 (MCID).
- 为特定终点确定有效的干预类型.
主要方法:
- 在多个数据库和试验记录中进行系统搜索 (PROSPERO ID:CRD42023468128).
- 纳入随机对照试验 (RCT) 在老年人群与肉类症,公布到2023年10月.
- 对最常见的结果进行的元分析.
主要成果:
- 分析了90个出版物,揭示了各种诊断标准,干预措施和设置.
- 身体表现/力量和身体构成是最常见的结果.
- 观察到很高的异质性;MCID很少被定义.
- 分析显示,对定时并进行测试 (TUG),尾骨肌指数 (ASMI),手握强度和椅子上升测试 (CRT) 的中度影响.
- 短物理性能电池 (SPPB) 没有显著影响.
结论:
- 萨科佩尼亚干预研究中的高异质性阻碍了干预疗效的可比性.
- 这些发现支持了使用ESCEO建议作为基础的核心结果和预定义的共同终点的必要性.
- 需要更一致的数据来进行在肉病研究中的强大元分析.
相关概念视频
01:19The Effect of Aging on Tissues
3.6K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
3.6K
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
400
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
400
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
367
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
367
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324